Sector Expert: Grant Zeng

Zacks Investment Research , Zacks Small-Cap Research

Image: Grant Zeng

Grant Zeng has more than 10 years' professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc., and has been with Zacks since March 2006. Before joining Zacks, Zeng worked for TheStreet.com as a biotech analyst from 2005-2006. From September 2001 to December 2003, Zeng worked for China Pacific Insurance Co. as an equity/fund analyst. Zeng was a healthcare equity analyst with Young & Partners LLC from August 2000 to September 2001. Zeng also has teaching and research experience in pharmaceutical science. Zeng obtained his master's of business administration with a major in finance in 2000 from McMaster University, Canada. He also holds a master's degree in biochemistry from the University of Western Ontario, Canada, and earned a master's degree in pharmacology and bachelor's degree in medicine from Second Military Medical University in China. Zeng is a Chartered Financial Analyst (CFA).



Recent Interviews

Build Biotech Wealth on Solid Platforms: Grant Zeng (4/17/14)

Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination.

6 Biotechs with Staggering Potential: Grant Zeng (4/4/13)

When it comes to picking biotech stocks, does a buyside perspective matter more than a sellside? Not according to Zacks Investment Research Analyst Grant Zeng, who has straddled the divide. What really matters is research of uncompromised quality. In this interview with The Life Sciences Report, Zeng offers a primer on what he looks for in a biotech investment, and names companies with the potential for big returns.

Recent Quotes

"DRRX's total revenue for Q2/18 was $3.4M."

— Grant Zeng, Zacks Small-Cap Research (8/6/18)
more >

"For Q4/17, DRRX recorded revenue of $19.5M compared to $3.5M in Q4/16."

— Grant Zeng, Zacks Small-Cap Research (3/2/18)
more >

"DRRX's total revenue of $20.7M in Q3/17 compares to $3.7M in Q3/16."

— Grant Zeng, Zacks Small-Cap Research (11/2/17)
more >

"We continue to be positive about DRRX's story."

— Grant Zeng, Zacks Small-Cap Research (10/25/17)
more >

"We think the patent purchase agreement is a great deal for DRRX."

— Grant Zeng, Zacks Equity Research (10/2/17)
more >

"We continue to be optimistic about DRRX's story."

— Grant Zeng, Zacks Equity Research (8/10/17)
more >

"We think DRRX and Sandoz' commercialization agreement is a great deal for DRRX."

— Grant Zeng, Zacks Equity Research (5/18/17)
more >

"We think this development and commercialization agreement with Sandoz AG is a great deal for DRRX."

— Grant Zeng, Zacks Equity Research (5/8/17)
more >

more comments

"We continue to be optimistic about DRRX's story."

— Grant Zeng, Zacks Equity Research (5/3/17)
more >

"Among DRRX's multiple candidates, we are especially optimistic about the epigenomic regulator program DUR-928, which holds great potential for multiple indications, such as NASH and acute kidney injury."

— Grant Zeng, Zacks Equity Research (3/15/17)
more >

"DRRX's DUR-928 holds great market potential for multiple indications."

— Grant Zeng, Zacks Small-Cap Research (2/15/17)
more >

"DRRX's DUR-928 is the most important program for Durect and the key value driver for the company in the long run."

— Grant Zeng, Zacks Equity Research (11/1/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.